Tetrabenazine clinical trial phase development?

Short answer: Tetrabenazine has completed the classic clinical-trial pathway (Phase I–III) and was approved in 2008 for Huntington disease–associated chorea. It is not currently in Phase III development for Huntington’s, and its main use today is as an approved therapy with Phase IV/post-marketing experience. Newer VMAT2 inhibitors (deutetrabenazine and valbenazine) have since been developed for related movement disorders.

Brief phase-by-phase history:
- Phase I: Safety, tolerability, and pharmacokinetics established in healthy volunteers and a small HD patient set; identified initial dosing ranges and common adverse effects (e.g., sedation, mood changes).
- Phase II: Dose-ranging studies in Huntington chorea to assess efficacy signals and refine dosing; helped characterize adverse effects.
- Phase III: Two pivotal double-blind, placebo-controlled trials in Huntington’s chorea showing reductions in chorea scores (and some functional effects) with tetrabenazine; adverse effects included depression, somnolence, parkinsonism-like symptoms, akathisia, and weight loss.
- Regulatory: FDA approval in 2008 for Huntington chorea. Post-marketing (Phase IV) data have continued to characterize safety in broader patient populations.
- Other indications: There have been smaller studies for Tourette syndrome and other hyperkinetic disorders, but tetrabenazine is not approved for those indications. Deutetrabenazine and valbenazine are newer VMAT2 inhibitors with different approvals and formulations.

If you want, I can look up the exact trial names and publication years for the Phase II/III Huntington chorea studies or summarize current regulatory status in other regions.